Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Tekla Life Sciences Investors (NYSE: HQL).

Full DD Report for HQL

You must become a subscriber to view this report.


Recent News from (NYSE: HQL)

Weekly Closed-End Fund Roundup: NBB/NBD And EMO/CBA Mergers Complete
The Weekly Closed-End Fund Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund [CEF] sectors in the last week, as well as to highlight recently concluded or upcoming corporate actions on CEFs, such as tender offers. Most of the information...
Source: SeekingAlpha
Date: December, 09 2018 16:27
Tekla Healthcare Opportunities Fund Paid Distribution
On November 30, 2018, Tekla Healthcare Opportunities Fund paid a monthly distribution of $0.1125 per share. It is currently estimated that this distribution is derived from net investment income, net realized long-term capital gains and return of capital or other capital source. The composit...
Source: Business Wire
Date: November, 30 2018 12:22
Tekla World Healthcare Fund Paid Distribution
On November 30, 2018, Tekla World Healthcare Fund paid a monthly distribution of $0.1167 per share. It is currently estimated that this distribution is derived from net investment income and return of capital or other capital source. The composition of this and subsequent distributions may v...
Source: Business Wire
Date: November, 30 2018 12:22
Tekla Life Sciences Investors: A High Quality Biotech Fund To Generate Solid Returns
Yesterday afternoon, I was watching a documentary discussing some of the recent advances in the fields of genetics and biotechnology. While some of the predictions seemed rather far-fetched (like being able to revitalize cells and effectively grant immortality by 2045), it still got me thinkin...
Source: SeekingAlpha
Date: November, 26 2018 11:43
Drug Pricing Reform Continues
By Ethan Lovell Portfolio Manager Ethan Lovell discusses a new proposal to overhaul drug pricing in Medicare Part B and what it could mean for drug manufacturers. Key Takeaways A proposal to lower drug costs would align Medicare Part B drug prices with prices outside the U.S., wher...
Source: SeekingAlpha
Date: November, 02 2018 05:35
The Biotech Bumps
We've turned the page to November, and investors across the globe may feel a bit of unconscious relief. Stock markets do fluctuate, but months like October are never fun. And that has been especially acute in biotech. Leading ETFs like IBB and XBI dropped ~15% and 18% respectively in October...
Source: SeekingAlpha
Date: November, 01 2018 08:00
President promises lower drug prices
Speaking at the Department of Health & Human Services, the president says both consumers and the government can save money if drugs were priced along the lines of that of other countries (i.e., Canada). More news on: iShares Nasdaq Biotechnology ETF, Health Care Select Sect SPDR ETF,...
Source: SeekingAlpha
Date: October, 25 2018 14:32
Tekla Life Sciences Investors Paid Distribution
On September 28, 2018, Tekla Life Sciences Investors paid a distribution of $0.40 per share. It is currently estimated that this distribution is derived from net realized short-term capital gains and return of capital or other capital source. The composition of this and subsequent distributi...
Source: Business Wire
Date: September, 28 2018 15:07
Tekla Healthcare Investors Paid Distribution
On September 28, 2018, Tekla Healthcare Investors paid a distribution of $0.47 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it ma...
Source: Business Wire
Date: September, 28 2018 15:07
New Innovation Spurring A Biotech Rejuvenation
By Evan McCulloch, Senior Vice President, Director of Research Franklin Equity Group ® Portfolio Manager, Franklin Biotechnology Discovery Fund Franklin Equity Group's Evan McCulloch explains why higher rates of drug utilization and healthcare spending are lending support to the b...
Source: SeekingAlpha
Date: September, 26 2018 06:26

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1016.9916.6517.020516.44151,477
2018-12-0717.3417.0317.3716.9273,749
2018-12-0617.3117.3417.381517.08123,301
2018-12-0417.8317.5118.0117.44134,322
2018-12-0317.9917.7918.019917.79108,788

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-108,10314,71955.0513Short
2018-12-078,46411,86071.3659Short
2018-12-061,6244,45136.4862Short
2018-12-042,27814,42315.7942Cover
2018-12-034,2135,69174.0292Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HQL.


About Tekla Life Sciences Investors (NYSE: HQL)

Logo for Tekla Life Sciences Investors (NYSE: HQL)

Not available

 

Contact Information

 

 

Current Share Structure

     


    Recent Filings from (NYSE: HQL)

    Quarterly Schedule of Portfolio Holdings of Registered Management Investment Company
    Filing Type: N-QFiling Source: edgar
    Filing Date: August, 28 2018
    Annual Report of Proxy Voting Record of Registered Management Investment Company
    Filing Type: N-PXFiling Source: edgar
    Filing Date: August, 20 2018
    Semi-Annual Report of a Certified Shareholder Report of registered investment management companies
    Filing Type: N-CSRSFiling Source: edgar
    Filing Date: June, 01 2018
    Semi-Annual report for management companies
    Filing Type: NSAR-AFiling Source: edgar
    Filing Date: May, 25 2018
    Additional proxy soliciting materials - definitive
    Filing Type: DEFA14AFiling Source: edgar
    Filing Date: April, 25 2018
    Post-effective amendment filed solely to add exhibits to a registration statement
    Filing Type: POS EXFiling Source: edgar
    Filing Date: April, 18 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 18 2018
    Quarterly Schedule of Portfolio Holdings of Registered Management Investment Company
    Filing Type: N-QFiling Source: edgar
    Filing Date: February, 23 2018
    Annual Certified Shareholder Report of Registered investment management companies
    Filing Type: N-CSRFiling Source: edgar
    Filing Date: December, 05 2017
    Annual report for management companies
    Filing Type: NSAR-BFiling Source: edgar
    Filing Date: November, 27 2017

     

     


    Daily Technical Chart for (NYSE: HQL)

    Daily Technical Chart for (NYSE: HQL)


    Stay tuned for daily updates and more on (NYSE: HQL)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NYSE: HQL)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HQL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of HQL and does not buy, sell, or trade any shares of HQL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/